In November 2025, Vanguard announced a broad reduction in the management fee of its suite of all-in-one funds, including its rival to XEQT, the Vanguard All-Equity ETF Portfolio ( VEQT:CA ).
The iShares Biotechnology ETF offers diversified exposure to the biotech sector, focusing on large-cap leaders while maintaining positions in smaller innovators. IBB is cap-weighted and top-heavy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results